On behalf of the undersigned organizations representing diverse patient and provider stakeholders who are concerned with the effects of rebate walls on patient treatment access, we greatly appreciate your leadership on critical efforts to protect patient well-being. We are pleased that you have requested that the Government Accountability Office (GAO) examine the effects of rebate walls on pharmaceutical prices and competition and that this is a focus issue for you and your staff. The critical need for this review is especially heightened during the ongoing COVID-19 pandemic as millions of Americans face financial uncertainty and obstacles to care and treatments.
